JP2023550035A - がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ - Google Patents

がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ Download PDF

Info

Publication number
JP2023550035A
JP2023550035A JP2023528148A JP2023528148A JP2023550035A JP 2023550035 A JP2023550035 A JP 2023550035A JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023550035 A JP2023550035 A JP 2023550035A
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
cdk4
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550035A5 (https=
Inventor
コーニーリアス ピーター
シャナハン ジェイムズ
ジェイ．カーバー ブラッドリー
Original Assignee
シンデブルックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンデブルックス，インコーポレイティド filed Critical シンデブルックス，インコーポレイティド
Publication of JP2023550035A publication Critical patent/JP2023550035A/ja
Publication of JP2023550035A5 publication Critical patent/JP2023550035A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2023528148A 2020-11-11 2021-11-10 がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ Pending JP2023550035A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US63/112,217 2020-11-11
US202163166060P 2021-03-25 2021-03-25
US63/166,060 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023550035A true JP2023550035A (ja) 2023-11-30
JP2023550035A5 JP2023550035A5 (https=) 2024-11-12

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528148A Pending JP2023550035A (ja) 2020-11-11 2021-11-10 がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ

Country Status (8)

Country Link
US (1) US20230404963A1 (https=)
EP (1) EP4243807A1 (https=)
JP (1) JP2023550035A (https=)
KR (1) KR20230117574A (https=)
AU (1) AU2021378944A1 (https=)
CA (1) CA3198173A1 (https=)
MX (1) MX2023005501A (https=)
WO (1) WO2022103834A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CA3264343A1 (en) * 2022-08-10 2024-02-15 Syndevrx, Inc. METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates
JP2019501206A (ja) * 2016-01-11 2019-01-17 シンデブルックス，インコーポレイティド 代謝機能不全によって引き起こされる腫瘍の治療
WO2020087077A1 (en) * 2018-10-26 2020-04-30 Syndevrx,Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates
JP2019501206A (ja) * 2016-01-11 2019-01-17 シンデブルックス，インコーポレイティド 代謝機能不全によって引き起こされる腫瘍の治療
WO2020087077A1 (en) * 2018-10-26 2020-04-30 Syndevrx,Inc. Biomarkers of metap2 inhibitors and applications thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.80, No.16_Supplement, JPN6025044006, 15 August 2020 (2020-08-15), ISSN: 0005717864 *
CHEN XIU; ET AL: "LATEST OVERVIEW OF THE CYCLIN-DEPENDENT KINASES 4/6 INHIBITORS IN BREAST CANCER: THE PAST, 以下備考", JOURNAL OF CANCER, vol. VOL:10, NR:26, JPN5024005604, 2019, AU, pages 6608 - 6617, ISSN: 0005717862 *
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, JPN6025044005, 21 July 2020 (2020-07-21), pages 1 - 15, ISSN: 0005717863 *

Also Published As

Publication number Publication date
AU2021378944A1 (en) 2023-06-15
US20230404963A1 (en) 2023-12-21
MX2023005501A (es) 2023-07-27
EP4243807A1 (en) 2023-09-20
WO2022103834A1 (en) 2022-05-19
KR20230117574A (ko) 2023-08-08
CA3198173A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CN113439078B (zh) Fxr激动剂的固体形式
CN108314677B (zh) 一种ezh2抑制剂及其用途
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
US12419846B2 (en) Biomarkers of METAP2 inhibitors and applications thereof
CN106456580B (zh) 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
WO2019127008A1 (zh) 一种靶向降解btk的化合物及其应用
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
KR20180042356A (ko) 암 치료 방법
JP2022521081A (ja) Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
JP2023550035A (ja) がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ
EP4469054A1 (en) Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
US10287294B2 (en) Compounds for use in treating or preventing cancerous diseases
WO2015197006A1 (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
WO2023241640A1 (zh) 一类靶向去泛素化酶usp25和usp28的小分子抑制剂
EP2867201A1 (en) Lim kinase inhibitors
JP7755347B2 (ja) 腎癌の標的治療のための新規化合物及び組成物
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
KR102053933B1 (ko) Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
CN111138426A (zh) 吲唑类激酶抑制剂及其用途
WO2025001852A1 (zh) 多肽偶联物、包含所述多肽偶联物的药物组合物及其用途
KR20250006934A (ko) 고형 종양을 치료하기 위한 이중 선택적 pi3k 델타 및 감마 억제제 및/또는 염-유도성 키나제 3 억제제
CN121591767A (zh) 一种含有碳硼烷的化合物及其用途
HK40122633A (zh) Jak抑制剂类似物、制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420